Search the Newsreel

Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...

This article first appeared on GuruFocus. Total Revenues: Approximately $629 million for Q2 2026. Cabozantinib Franchise Net Product Revenues (US): $573 million, up approximately 10% year-over-year. Global Cabozantinib Franchise Net Product Revenues (Exelixis and partners): $806 million, up approximately 13% year-over-year. CABOMETYX Net Product …

Exelixis (EXEL) Tops Q2 Earnings Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Exelixis Q2 2026 earnings: Cabozantinib growth lifts revenue and EPS

Exelixis reported strong Q2 2026 earnings, with revenue reaching $628.7 million, a 10.6% increase year-over-year, and diluted EPS rising to $0.82. This growth was primarily driven by higher sales volume of cabozantinib, though the company lowered its full-year revenue outlook. Exelixis continues to invest …

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Exelixis reported strong second-quarter 2026 financial results, with total revenues reaching $628.7 million and GAAP diluted EPS of $0.82. The company highlighted the continued growth of its cabozantinib franchise and significant progress in its zanzalintinib development program, including ongoing regulatory review for metastatic colorectal …

Transcript : Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026

This article is a transcript of Exelixis, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. During the call, Exelixis updated its fiscal 2026 revenue guidance to $2.50B-$2.55B, lower than FactSet's estimate of $2.60B. The company also reported Q2 revenue of $628.7M and …

Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M

Exelixis, Inc. (EXEL) reported its Q2 revenue at $628.7 million, falling short of the FactSet estimate of $636.4 million. The company also updated its fiscal year 2026 revenue guidance to a range of $2.50 billion to $2.55 billion, which is below the FactSet estimate …

Exelixis earnings on deck as generic threat looms

Exelixis Inc. is set to report second-quarter earnings, facing scrutiny over its flagship cancer drug, Cabometyx, due to an escalating patent dispute and the emergence of a generic alternative. Investors are also keenly watching the commercialization prospects for its next-generation pipeline drug, zanzalintinib, and …

Royal Bank of Canada Grows Stock Holdings in Exelixis, Inc. $EXEL

Royal Bank of Canada increased its holdings in Exelixis, Inc. by 24.6% in the first quarter, now owning 694,131 shares valued at approximately $29.8 million. This increase comes as Exelixis reported strong quarterly earnings, beating analyst estimates, with revenue up 10% year-over-year. Despite recent …

Exelixis (EXEL) Stock Still Looks Cheap On Earnings While Returns Look Rich

Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Elixirr International Plc Revenue Breakdown – LSE:ELIX

Exelixis, Inc. $EXEL Shares Sold by Private Client Services LLC

Private Client Services LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 40.9% in the second quarter, selling 19,576 shares. Despite this, Exelixis reported strong quarterly earnings of $0.87 per share, surpassing estimates, with revenue increasing 10% year over year to $610.81 million. The …

Fujian Haixi Pharmaceuticals Co., Ltd. Approves Election of Chen Tingze as Executive Director, Effective August 4, 2026

Fujian Haixi Pharmaceuticals Details Board and Committee Structure

Haixi Pharmaceuticals Advances Oral nAMD Drug HX9428 With U.S. FDA Nod and New China Trial

Fujian Haixi Pharma Shareholders Back Auditor Switch and New Executive Director

Exelixis Inc expected to post earnings of 79 cents a share - Earnings Preview

Exelixis Inc. is anticipated to report earnings of 79 cents per share. This information is provided as an earnings preview from Reuters, accessible via TradingView. The full article is available with unlimited access on TradingView.

Elixirr earnings hike; Winvia-Aston Villa tie-up

Exelixis stock rating maintained at Market Outperform by Citizens

Citizens has maintained a Market Outperform rating and a $55.00 price target for Exelixis (NASDAQ:EXEL), noting that the stock appears undervalued according to InvestingPro analysis. The article also discusses the ongoing patent dispute between Exelixis and Handa Oncology regarding a new cabozantinib formulation and …

Fujian Haixi Pharmaceuticals Details Significant 2025 Investment Portfolio

Elixir Energy’s Lorelle-3H Flow Test Confirms Taroom Trough Gas Potential

Elixirr International (ELIX) Achieves Record £89m H1 2026 Revenue, Up 25%, and Names Canaccord Genuity as Joint Broker

Elixirr shares climb 9% on record half as AI consulting demand builds

Exelixis, Inc. Revenue Breakdown – NASDAQ:EXEL

Exelixis, Inc. (EXEL) generated $2.32 billion in revenue last year, primarily from its "Medicines for Difficult-to-treat Cancers" segment. This represents an increase from $2.17 billion in the previous year. The United States was the largest contributor to revenue, accounting for $2.14 billion.

Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis

Exelixis Inc (EXEL) has a strong financial health score of 8.96, ranking 22nd in the Biotechnology & Medical Research industry. The company reported a quarterly revenue of $610.81 million, marking a 9.97% year-over-year increase, and its net profit rose by 31.86% year-over-year. This indicates …

Zhixin HK Connect Active Trading | July 31

Exelixis (EXEL) Slides as Investors Likely Take Profits Ahead of Earnings

Labixiaoxin Snacks Group Ltd. Revenue Breakdown – HKEX:1262

Exelixis Inc (EXEL) Institutional Confidence

Exelixis Inc (EXEL) has an institutional shareholding score of 10.00, placing it first among 384 companies in the Biotechnology & Medical Research industry. The total institutional shareholding increased by 9.40% quarter-over-quarter, reaching 107.76%. James Simons is the largest institutional shareholder, holding 5.40% of shares …

Law firm probes EXELIXIS officers for possible self-dealing, urging shareholders to act.

Kuehn Law, PLLC is investigating EXELIXIS, Inc. officers and directors for potential breaches of fiduciary duties, specifically concerning self-dealing. The firm is encouraging long-term shareholders to contact them to explore potential damages and governance reforms. Shareholders are advised to act quickly due to possible …

Exelixis Inc (EXEL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Exelixis Inc (EXEL), highlighting its current score of 7.37, which ranks it 13th out of 384 in the Biotechnology & Medical Research industry. Key metrics such as beta value, VaR, maximum drawdown, volatility, and Sharpe ratio are …

(EXEL) Risk Channels and Responsive Allocation

The article provides a detailed analysis of Exelixis Inc. (NASDAQ: EXEL), identifying a neutral near and mid-term outlook but a positive long-term bias. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis highlights key signals, …

EXEL|Exelixis Inc|Price:55.505|Chg%:+0.175

This article provides a comprehensive stock analysis of Exelixis Inc (EXEL) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The analysis also mentions high institutional ownership, recent "Buy" ratings from …

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. (NASDAQ: EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to …

Exelixis, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh Revenue Breakdown – BMFBOVESPA:E2XE34

This article provides a revenue breakdown for Exelixis, Inc.'s Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BMFBOVESPA:E2XE34). It highlights that the United States was the greatest contributor to the company's revenue, accounting for 11.96 billion BRL last year, up from 9.84 billion BRL the …

Exelixis Inc (EXEL) Income Statement

This article provides the quarterly and annual income statements for Exelixis Inc (EXEL), offering detailed financial data such as revenue, operating expenses, net income, and earnings per share. It also includes frequently asked questions to help users interpret the financial information presented on the …